Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil falls 1% as investors watch Middle East supply disruptions
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Acadia Pharma (ACAD) to stop pimavanserin trials after failure
March 12, 2024 12:52 PM EDTShares of Acadia Pharma (NASDAQ: ACAD) plunged Tuesday after the company reported after the close on Monday that its Phase 3 ADVANCE-2 trial did not meet its primary endpoint.
The company's stock price is down more than 15% at $20.48 per share following the news.
The Phase 3 ADVANCE-2 trial was... More
Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
March 12, 2024 4:51 AM EDTMizuho analyst Uy Ear downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $25.00 (from $39.00).
The analyst comments "Given the failed ADVANCE-2 trial, we remove our sales forecast for Nuplazid in negative symptoms of schizophrenia (NSS). With NSS... More
Acadia Pharma (ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary Endpoint
March 11, 2024 4:10 PM EDTAcadia Pharma (NASDAQ: ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary Endpoint
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of... More